Proteo Biotech AG
Proteo, Inc. / Proteo Biotech AG: EMPIRE-Study recruits first coronary bypass patients
Proteo Biotech AG / Key word(s): Study/Research Update Proteo, Inc. / Proteo Biotech AG: EMPIRE-Study recruits first coronary bypass patients Irvine, CA – Kiel, 16th August, 2011 Proteo, Inc. (OTCQB: PTEO; Freiverkehr Frankfurt: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG announced today: The first two patients have been recruited into the EMPIRE-Study which will investigate the efficacy of the naturally occurring human protease inhibitor Elafin in preventing complications of coronary bypass surgery. 'We are optimistic that Elafin will reduce cardiac muscle injury and post-operative inflammatory responses in patients receiving a bypass', commented Professor Oliver Wiedow, chairman of the supervisory board of Proteo Biotech AG, a company specializing in the research and development of new pharmaceuticals with emphasis on anti-inflammatory substances. The study is being performed under the supervision of the cardiologist Dr. Peter Henriksen at NHS Lothian's Edinburgh Heart Centre in association with The University of Edinburgh, one of the leading European universities in the area of cardiovascular research, and the Edinburgh Clinical Trials Unit. The aim of the study is to investigate the efficacy and safety of intraoperatively administered Elafin in coronary bypass surgery. Inflammation of cardiac muscle and the resulting muscle injury after a bypass operation remain a frequent and unresolved problem. EMPIRE (Elafin Myocardial Protection from Ischaemia Reperfusion Injury) is a placebo-controlled, double-blinded, monocentric Phase-II study with 80 patients. The study will be funded by the Medical Research Council (MRC) and Chest Heart & Stroke Scotland (CHSS) with funding in excess of 500,000 GBP.
Further information on the clinical development program for Elafin:
About Proteo:
Forward-looking statements:
Contact:
Email: info@proteo.de End of Corporate News 16.08.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
135825 16.08.2011 |